The Anova Health Institute, which received the lion’s share of the US President’s Emergency Plan for Aids funding in South Africa, had its support halted in February along with dozens other nonprofits
A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while
Cancellation letters, which end millions of rands of South African universities’ US-government funded HIV and TB research grants with immediate effect, started to roll in over the weekend
CAB-LA virtually eliminates someone’s chances of contracting HIV, but costs about four times more than the government can afford to pay
The CAB-LA injection is the first of its kind in HIV prevention interventions and only needs to be taken every eight weeks
New research from seven countries in Africa signals the future of HIV prevention — but what can it learn from its past?